Colorado is currently home to 1810 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Denver, Aurora, Colorado Springs and Englewood. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Pediatric Oncology Recovery Trial After Surgery
NCT04344899
Recruiting
Pediatric Oncologic Recovery Trial After Surgery (PORTS) trial is an investigator-initiated, multicenter, multidisciplinary prospective case-control study of the implementation of an Enhanced Recovery After Surgery (ERAS) protocol at five tertiary-care pediatric hospitals in pediatric patients undergoing abdominal or retroperitoneal surgical resections for cancer. A pilot phase will determine characteristics of a successful protocol implementation and an exploratory phase plans to examine adhere... Read More
Gender:
ALL
Ages:
Between 1 month and 18 years
Trial Updated:
02/06/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Pelvic Cancer
Register for Updates
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC
NCT06228924
Recruiting
This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/05/2025
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients with CtDNA-positive, Resected Stage II (high Risk) and Stage III Colorectal Cancer
NCT04486378
Recruiting
This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Rocky Mountain Cancer Centers - Denver Midtwon, Denver, Colorado
Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Register for Updates
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
NCT04045665
Recruiting
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their ba... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Medical Center of Aurora, Aurora, Colorado
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
NCT03042221
Recruiting
A comparison of baseline tumor characteristics in oncogene-driven cancers to tumor characteristics after early response to Tyrosine Kinase Inhibitor (TKI) targeted treatment will allow identification of early adaptive mechanisms of cell survival. This will facilitate targeting and termination of these survival/ resistance pathways before they develop with rational combinations of therapeutic agents to improve outcomes.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/05/2025
Locations: University of Colorado, Cancer Center, Aurora, Colorado
Conditions: Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Register for Updates
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
NCT01580982
Recruiting
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/05/2025
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Lung Neoplasms
Register for Updates
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
NCT04762641
Recruiting
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary antitumor activity, and the PD effect of ABL503 in subjects with any progressive locally advanced (unresectable) or metastatic solid tumors who are relapsed or refractory following the last line of treatment and have no available standard of care option. This study includes 3... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado
Conditions: Advanced Solid Tumor
Register for Updates
Retrospective Analysis of Prismaflex HF20 Set Versus ppCRRT Registry
NCT06633029
Recruiting
A retrospective multicenter, observational design intended to capture data on pediatrics (weighing between 8 - 20 kg) who underwent continuous renal replacement therapy (CRRT) using the HF20 set. Data will be compared with a similar population (weighting 8-20 kg) from the ppCRRT registry who received CRRT with Prismaflex M60 sets.
Gender:
ALL
Ages:
All
Trial Updated:
02/03/2025
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Acute Renal Failure (ARF), Acute Kidney Injury (AKI), Fluid Overload in Dialysis Patients
Register for Updates
Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype
NCT06532734
Recruiting
To better define the presence of Barrett's esophagus (BE) via non-endoscopic testing in an eating disorder cohort with purging (vomiting/rumination) behaviors
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/03/2025
Locations: ACUTE Center for Eating Disorders and Severe Malnutrition, Denver, Colorado
Conditions: Barrett Esophagus, Anorexia Nervosa, Binge Eating/Purging Type, Rumination, Vomiting, Eating Disorders, Esophageal Adenocarcinoma
Register for Updates
Interventions to De-implement Unnecessary Antibiotic Prescribing for Children With Ear Infections
NCT06034080
Recruiting
This study aims to improve care and reduce unnecessary antibiotic prescribing for children with ear infections. The study will compare the effectiveness of a "gold standard" to a hybrid intervention combined with this gold standard, in order to identify steps to increase parent satisfaction for child ear infection care. The "gold standard" approach is a Health System Level Intervention. On its own, it involves clinician education, tools in electronic medical records, and audit and feedback repor... Read More
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
02/03/2025
Locations: Denver Health and Hospital Authority, Denver, Colorado
Conditions: Acute Otitis Media, Ear Infection, Pediatric Infectious Disease
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Colorado Heart and Vascular, Golden, Colorado
Conditions: Coronary Artery Disease
Register for Updates
Study of PYX-201 in Solid Tumors
NCT05720117
Recruiting
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: SCRI - HealthOne Denver, Denver, Colorado
Conditions: Solid Tumor, Advanced Solid Tumor
Register for Updates